Enanta Pharmaceuticals Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Enanta Pharmaceuticals filed its Q2 2024 10-Q, detailing financial performance and corporate information.</b>

AI Summary

ENANTA PHARMACEUTICALS INC (ENTA) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Enanta Pharmaceuticals filed its 10-Q report for the period ending March 31, 2024. The filing covers the second quarter of fiscal year 2024. Key financial statement data points and dates are referenced within the filing. The company's principal executive offices are located at 500 Arsenal Street, Watertown, MA. The filing includes information related to various financial instruments and equity components.

Why It Matters

For investors and stakeholders tracking ENANTA PHARMACEUTICALS INC, this filing contains several important signals. This 10-Q provides investors with the latest quarterly financial results and operational updates for Enanta Pharmaceuticals. Understanding the details within this filing is crucial for assessing the company's current financial health and future prospects.

Risk Assessment

Risk Level: low — ENANTA PHARMACEUTICALS INC shows low risk based on this filing. The filing is a standard 10-Q, providing routine financial disclosures without immediate red flags.

Analyst Insight

Review the detailed financial statements and risk factors in the 10-Q to understand Enanta's current financial position and strategic direction.

Key Numbers

• 2024-03-31 — Period End Date (Quarterly period)
• 2024-05-08 — Filing Date (Date of submission)
• Q2 — Fiscal Quarter (Indicates the second quarter)
• 2024 — Fiscal Year (Indicates the fiscal year)

Key Players & Entities

• ENANTA PHARMACEUTICALS INC (company) — Filer name
• 2024-03-31 (date) — Period of report
• 2024-05-08 (date) — Filing date
• 500 ARSENAL STREET (address) — Business address
• WATERTOWN (location) — Business address city
• MA (state) — Business address state
• 02472 (zip_code) — Business address zip
• AbbVie (company) — Mentioned in relation to financial periods

FAQ

Industry Context

Enanta Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on the development of small molecule anti-infective drug candidates.

Regulatory Implications

As a publicly traded pharmaceutical company, Enanta is subject to SEC regulations and reporting requirements, including the filing of quarterly 10-Q reports.

What Investors Should Do

1. Analyze the financial statements for revenue, expenses, and cash flow.
2. Review any disclosed risk factors and management's discussion and analysis.
3. Compare key metrics to previous periods and industry benchmarks.

Year-Over-Year Comparison

This filing represents the quarterly update for the period ending March 31, 2024, following previous filings.

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share ENTA NASDAQ Indicate by

Filing Documents

• enta-20240331.htm (10-Q) — 1564KB
• enta-ex10_2.htm (EX-10.2) — 32KB
• enta-ex31_1.htm (EX-31.1) — 11KB
• enta-ex31_2.htm (EX-31.2) — 11KB
• enta-ex32_1.htm (EX-32.1) — 10KB
• img216959928_0.jpg (GRAPHIC) — 630KB
• 0000950170-24-055581.txt (&nbsp;) — 7924KB
• enta-20240331.xsd (EX-101.SCH) — 925KB
• enta-20240331_htm.xml (XML) — 1185KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 27 Item 4.

Controls and Procedures

Controls and Procedures 27 PART II. OTHER INFORMATION Item 1A.

Risk Factors

Risk Factors 27 Item 5. Other Information 27 Item 6. Exhibits 29

Signatures

Signatures 30 NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q ("Quarterly Report") contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, forward-looking statements may be identified by words such as "anticipate," "believe," "continue," "could," "design," "estimate," "expect," "intend," "may," "plan," "potentially," "predict," "project," "should," "will" or the negative of these terms or other similar expressions. We caution you that the foregoing list may not encompass all of the forward-looking statements made in this Quarterly Report. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions, including risks described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2023, our subsequently filed Quarterly Reports on Form 10-Q and as updated in Item 1A herein. 2 PAR T I—UNAUDITED FINANCIAL INFORMATION IT EM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ENANTA PHARMACEUTICALS, INC. CONDENSED CONS OLIDATED BALANCE SHEETS (unaudited) (in thousands, except per share data) March 31, September 30, 2024 2023 Assets Current assets: Cash and cash equivalents $ 63,542 $ 85,388 Short-term marketable securities 236,768 2

View Full Filing

View this 10-Q filing on SEC EDGAR